Passive immunization for immunocontraception: lessons learned from infectious diseases

10.2741/1407 ◽  
2004 ◽  
Vol 9 (1-3) ◽  
pp. 2457 ◽  
Author(s):  
Rajesh, K. Naz
Keyword(s):  
Infectious Diseases ◽  
Passive Immunization ◽  
Lessons Learned

scholarly journals Pandemic Prevention: Lessons from COVID-19

Encyclopedia ◽  
2021 ◽  
Vol 1 (2) ◽  
pp. 433-444
Author(s):  
Mario Coccia
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Infectious Diseases ◽  
Health System ◽  
Negative Impact ◽  
Lessons Learned ◽  
The Novel ◽  
Policy Responses

Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which appeared in late 2019, generating a pandemic crisis with high numbers of COVID-19-related infected individuals and deaths in manifold countries worldwide. Lessons learned from COVID-19 can be used to prevent pandemic threats by designing strategies to support different policy responses, not limited to the health system, directed to reduce the risks of the emergence of novel viral agents, the diffusion of infectious diseases and negative impact in society.

Antisera, Toxoids, Vaccines and Tuberculins in Prophylaxis and Treatment

PEDIATRICS ◽  
1959 ◽  
Vol 23 (2) ◽  
pp. 430-430
Author(s):  
C. ARDEN MILLER
Keyword(s):  
Infectious Diseases ◽  
Passive Immunization ◽  
Active Immunization ◽  
Biological Products

This book begins: "Biological products used in infectious diseases may be divided into three groups, namely: 1) Sera of various types for prophylaxis and treatment by passive immunization; 2) Prophylactics, such as toxins, toxoids, and vaccines (both bacterial and viral), for active immunization; 3) Diagnostic products, such as diluted toxins and tuberculins, used by the clinician to detect the presence or absence of immunity and also of allergy. Most of these materials come within the scope of this book.

scholarly journals Lessons learned from the first European project on the integration of infectious diseases in testing services, data collection and country responses

2021 ◽  
Vol 21 (S2) ◽  
Author(s):  
Dorthe Raben ◽  
Jordi Casabona ◽  
Lella Cosmaro ◽  
Nadia Gasbarrini ◽  
John S. Lambert ◽  
...  
Keyword(s):  
Data Collection ◽  
Infectious Diseases ◽  
Lessons Learned ◽  
European Project

scholarly journals Passive immunization in the combat against infectious diseases (COVID-19 included)

2021 ◽  
Vol 14 (2) ◽  
pp. 50-57
Author(s):  
Joanna Lasocka ◽  
Artur Bielawski ◽  
Elżbieta Lachert
Keyword(s):  
Infectious Diseases ◽  
Passive Immunization

scholarly journals Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer’s Disease

Biology ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 425
Author(s):  
Francesca Mantile ◽  
Antonella Prisco
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Infectious Diseases ◽  
Adaptive Immune Response ◽  
Immunological Response ◽  
Vaccination Strategy ◽  
Active Immunization ◽  
Lessons Learned ◽  
Phase Iii ◽  
Β Amyloid

Vaccination relies on the phenomenon of immunity, a long-term change in the immunological response to subsequent encounters with the same pathogen that occurs after the recovery from some infectious diseases. However, vaccination is a strategy that can, in principle, be applied also to non-infectious diseases, such as cancer or neurodegenerative diseases, if an adaptive immune response can prevent the onset of the disease or modify its course. Immunization against β-amyloid has been explored as a vaccination strategy for Alzheimer’s disease for over 20 years. No vaccine has been licensed so far, and immunotherapy has come under considerable criticism following the negative results of several phase III clinical trials. In this narrative review, we illustrate the working hypothesis behind immunization against β-amyloid as a vaccination strategy for Alzheimer’s disease, and the outcome of the active immunization strategies that have been tested in humans. On the basis of the lessons learned from preclinical and clinical research, we discuss roadblocks and current perspectives in this challenging enterprise in translational immunology.

scholarly journals The technology behind TB DEPOT: a novel public analytics platform integrating tuberculosis clinical, genomic, and radiological data for visual and statistical exploration

2020 ◽  
Author(s):  
Alyssa Long ◽  
Alexander Glogowski ◽  
Matthew Meppiel ◽  
Lisa De Vito ◽  
Eric Engle ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
Clinical Research ◽  
Architectural Design ◽  
Application Programming Interface ◽  
Lessons Learned ◽  
Data Exploration ◽  
Multidimensional Data ◽  
Server Side ◽  
Wide Range ◽  
Clinical Research Informatics

Abstract Objective Clinical research informatics tools are necessary to support comprehensive studies of infectious diseases. The National Institute of Allergy and Infectious Diseases (NIAID) developed the publicly accessible Tuberculosis Data Exploration Portal (TB DEPOT) to address the complex etiology of tuberculosis (TB). Materials and Methods TB DEPOT displays deidentified patient case data and facilitates analyses across a wide range of clinical, socioeconomic, genomic, and radiological factors. The solution is built using Amazon Web Services cloud-based infrastructure, .NET Core, Angular, Highcharts, R, PLINK, and other custom-developed services. Structured patient data, pathogen genomic variants, and medical images are integrated into the solution to allow seamless filtering across data domains. Results Researchers can use TB DEPOT to query TB patient cases, create and save patient cohorts, and execute comparative statistical analyses on demand. The tool supports user-driven data exploration and fulfills the National Institute of Health’s Findable, Accessible, Interoperable, and Reusable (FAIR) principles. Discussion TB DEPOT is the first tool of its kind in the field of TB research to integrate multidimensional data from TB patient cases. Its scalable and flexible architectural design has accommodated growth in the data, organizations, types of data, feature requests, and usage. Use of client-side technologies over server-side technologies and prioritizing maintenance have been important lessons learned. Future directions are dynamically prioritized and key functionality is shared through an application programming interface. Conclusion This paper describes the platform development methodology, resulting functionality, benefits, and technical considerations of a clinical research informatics application to support increased understanding of TB.

Red Book (2015)

2015 ◽  
Keyword(s):  
Infectious Diseases ◽  
Antimicrobial Prophylaxis ◽  
Medical Center ◽  
Passive Immunization ◽  
High Yield ◽  
Injection Pain ◽  
Parasitic Infections ◽  
Health Providers ◽  
Pneumococcal Infections ◽  
Pediculosis Capitis

4-Star Review "This is an unparalleled resource in both content and authority for pediatric infectious diseases knowledge, from diagnosis to management and prevention." Kari A. Simonsen, MD, University of Nebraska Medical Center Doody's Book Review The AAP's authoritative guide to the manifestations, etiology, epidemiology, diagnosis, and treatment of more than 200 childhood conditions. The Red Book provides evidence-based guidance to practicing clinicians on pediatric infections and vaccinations based on the recommendations of the committee as well as the combined expertise of the CDC, the FDA and hundreds of physician contributors. The Red Book is an essential reference for pediatric infectious diseases specialists and general pediatricians, and is useful for family medicine and emergency medicine physicians as well. Public health and school health providers, medical residents and students also will find it a high-yield source of pediatric infectious disease and vaccine information. The book is divided into sections that cover * Active and passive immunization * Disease summaries * Antimicrobial therapy for treatment and prophylaxis * Care of children in special situations Updated information and recommendations you cannot afford to be without... * Standardized approach to disease prevention through immunizations, antimicrobial prophylaxis, and infection control practices * New chapter on Hemorrhagic Fevers Caused by Filoviruses has been added * New chapter on human parechovirus infections has been added * Updated information on hypersensitivity reactions after immunizations * The latest on sexually transmitted infections (STIs) in adolescents and children * Updated coverage of actinomycosis, amebiases, arbovirus, bacterial vaginosis, blastocystis, candidiasis, Clostridium difficle, coronaviruses, dengue, enteroviruses, Escherichia coli, Giardia intestinalis, gonococcal infections, Helicobacter pylori infections, lyme disease, meningococcal infections, pediculosis capitis, pertussis, pneumococcal infections, rotavirus, and more * Managing Injection Pain has been significantly expanded * Updated information on hepatitis C * Updated information on group B streptococcal infections * Updated section on drugs for parasitic infections * Significantly revised chapter on Respiratory Syncytial Virus * Recommendations for using MMR or MMRV vaccines have been updated * The Antimicrobial Resistance and Antimicrobial Stewardship chapter has been significantly broaded and updated * Updated information on HIV * And much more!

Sign in / Sign up

Export Citation Format

Share Document